Clinical Trial Update: Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating copanlisib with dose-adjusted EPOCH-R in relapsed and refractory Burkitt lymphoma and other high-grade B-cell lymphomas; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Germinal Center B-cell-like Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• T-cell Histiocyte-rich Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Copanlisib (copanlisib)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2024-07-09